#Abs0588 Effectiveness of TNFi vs non-TNFis in obese patients with #rheumatic disease @MilenaGianfran: 👉🏼>16000pts @ACRheum RISE 👉🏼Abatacept➡️larger decreases in CDAI in obese pts 👉🏼Tocilizumab➡️larger decreases in CDAI in non-obese pts @RheumNow #ACR21 https://t.co/bL5xnG1iNh

• Effectiveness of TNFi versus Non-TNFi Biologics on Disease Activity in Obese Pa…

B cell repertoire: the new 🔮? An algorithm associating baseline CDAI to BCR sequencing outcomes w/ ✨Isotypes frequency ✨Somatic Hypermutations predicts MTX 12mo response w/ 78% sens & spe #Abstr982 #ACR21 @RheumNow https://t.co/SZaip6xUaO https://t.co/fbWq34gtzc

• B Cells Repertoire Repartition Predicts Response to Methotrexate at 6 and 12 Mo…

#ACR21 #Abstr0866 Data from #COVID19 GRA Registry showed predictors of poor COVID outcome in 1922 #lupus pts: Older age Male Areas outside Europe, 🇺🇸🇨🇦 Infection <June 2020 Any Corticosteroid dose Not on therapy On Rituximab Comorbidities ⬆️disease activity @RheumNow #ACRBest https://t.co/u0GF3aDsFA

AxSpA pts who achieve ASDAS low disease activity (LDA) 6 mo after bDMARD initiation ⭐️ 25% achieved ASDAS LDA ⭐️ASDAS LDA achievers were ♂️ + naïve to c/b DMARDs + with PROM / Clinical improvement ⭐️ASDAS LDA non-achievers=depression, uveitis, IBD Abst# 0925 #ACR21 @RheumNow

#ACR21 Abst#0588. TNF vs non-TNFi in obese RA pts ⭐️TNFi use ⬆️ disease activity vs ABA in obese pts ⭐️TNFi use ⬆️ activity vs TCZ in non-obese pts ⭐️No diff w RTX, Tofa ▶️Further research needed: Wt-based dosing? SC vs IV? https://t.co/K8WycPTgxW @Rheumnow #ACRBest

• https://bit.ly/3H1GMDI

SEC reduced SIJ bone marrow edema in active nr-axSpA pts. Majority of pts both in SEC and PBO arms showed no radiographic progression through 2 years. Abs 0921 #ACR21 #RheumNow @RheumNow https://t.co/yC2AZoacxF https://t.co/pjCL8HCanR

• Effect of Secukinumab on Radiographic Progression and Inflammation in Sacroilia…

CARRA STOP-JIA 400pts, Obs study w/ 3 treatments plans : -Step up -Early combination -Biologic first Which one do you think works best? I'd say none: overall 40-60% not achieving CDI off steroids at 24 months. Results: 42% for SU, 52% EC, and 44% BF #Abtr0960 #ACR21 @RheumNow

Factors associated with Anti Drug Ab against TNFi over 2-y in axSpA pts are: ⭐️ 🔼 Disease activity ⭐️Development of adverse events ⭐️Treatment discontinuation Abst #0936 #ACR21 @RheumNow

Dr Naovarat reports on 18 year outcomes of HIV and rheumatic disease. 16 patients treated with TNFi, including 2 who switched to tocilizumab and ustekinumab. No major infections. Rising viral load in 1 led to discontinue. Abstr#0965 #ACR21 @RheumNow https://t.co/jcGPaURKmb

SKIPPAIN results: Spinal pain response after 8 weeks of SEC showed notable differences between HLA-B27 subgroups. Can subtype pre-determine tx efficacy/response? Abs 0917 #ACR21 #RheumNow @RheumNow https://t.co/FKpCqXpobM https://t.co/WbjjyTIaiG

• Efficacy of Secukinumab and HLA-B27 Subtypes: Results from a Phase IIIb Randomi…